AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30549418 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 30549425 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti-cardiac myosin (CM) antibody detected at transplantation and at 12 months
Number of subjects: 200
Study 30549425 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma VEGF-A levels pretransplant
Number of subjects: 200
Study 30549425 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma VEGF-C levels pretransplant
Number of subjects: 200
Study 30549425 — intervention group
Group type: COMPARATOR
Intervention: Early intravascular ultrasound findings or other candidate biomarkers
Number of subjects: 200
Study 30550345 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 30550345 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 0
Study 30551012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 31
Study 30551012 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 30551202 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonic anhydrase inhibitor (CAI) treatment
Number of subjects: 56
Study 30551202 — intervention group
Group type: COMPARATOR
Intervention: No treatment (natural history)
Number of subjects: 56
Study 30551910 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC pathway (A: Time in Therapeutic Range ≥65%; B: EHRA symptom scale I-II; C: optimized cardiovascular comorbidity management)
Number of subjects: 907
Study 30551910 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic patients (EHRA III-IV)
Number of subjects: 907
Study 30551910 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimally managed patients in the ABC group (n=198)
Number of subjects: 907
Study 30551910 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate Cox proportional regression analysis
Number of subjects: 907
Study 30552056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) in a single combination tablet once daily for 12 weeks
Number of subjects: 300
Study 30552056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir
Number of subjects: 300
Study 30552109 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotide knockdown (ASO-KD) of nicotinamide
Number of subjects: 0
Study 30552130 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) with autoantibodies (AAB)
Number of subjects: 0
Study 30552130 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) without autoantibodies (AAB)
Number of subjects: 0
Study 30552130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30552129 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30552135 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent-onset type 1 diabetes (T1D)
Number of subjects: 0
Study 30552135 — intervention group
Group type: COMPARATOR
Intervention: Control participants (without diabetes)
Number of subjects: 0
Study 30552156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine plus sorafenib
Number of subjects: 22
Study 30552156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine 280 mg/m2
Number of subjects: 22
Study 30552156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine 320 mg/m2
Number of subjects: 22
Study 30552511 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI with SAPIEN 3 transcatheter heart valves
Number of subjects: 235
Study 30552626 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized triage protocol
Number of subjects: 776
Study 30552626 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage process
Number of subjects: 776
Study 30553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food availability of healthful foods (fruits, vegetables, meats)
Number of subjects: 164
Study 30553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food availability of unhealthful foods (sugar-sweetened beverages)
Number of subjects: 164
Study 30553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dietary intake recommendations
Number of subjects: 164
Study 30553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility and purchasing frequency of foods
Number of subjects: 164
Study 30553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food environments (HFE)
Number of subjects: 164
Study 30553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations to improve dietary intake quality
Number of subjects: 164
Study 30554141 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 levels
Number of subjects: 30
Study 30554141 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 levels <564 pg/L
Number of subjects: 30
Study 30554141 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK1 inhibition with 5(Z)-7-oxozeaenol
Number of subjects: 30
Study 30554141 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 30
Study 30554418 — intervention group
Group type: EXPERIMENTAL
Intervention: InnFocus MicroShunt
Number of subjects: 889
Study 30554418 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 889
Study 30554548 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity measured by body mass index (BMI)
Number of subjects: 0
Study 30554548 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity measured by another unspecified measure
Number of subjects: 0
Study 30554571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate therapy
Number of subjects: 1303
Study 30554975 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing information needs and barriers to colorectal cancer screening
Number of subjects: 45
Study 30554975 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing preferences for information delivery
Number of subjects: 45
Study 30554975 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing fears and concerns regarding colonoscopy
Number of subjects: 45
Study 30554975 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing the use of patient portals
Number of subjects: 45
Study 30555051 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily, taken after haemodialysis for up to 96 weeks.
Number of subjects: 55
Study 30555051 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen.
Number of subjects: 55
Study 30555048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and Velpatasvir (100 mg) tablet once daily for 12 weeks
Number of subjects: 375
Study 30555280 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive administration of intravenous levosimendan after discharge from an acute episode of worsening heart failure.
Number of subjects: 0
Study 30555280 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for advanced heart failure.
Number of subjects: 0
Study 30555384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy modules
Number of subjects: 103
Study 30555384 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology modules
Number of subjects: 103
Study 30555714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Spinal Manipulative Therapy (SMT)
Number of subjects: 40
Study 30555714 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 40
Study 30555800 — intervention group
Group type: EXPERIMENTAL
Intervention: Piver Type II Hysterectomy
Number of subjects: 0
Study 30555800 — intervention group
Group type: COMPARATOR
Intervention: Piver Type III Hysterectomy
Number of subjects: 0
Study 30542662 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and care interventions for tuberculosis and HIV
Number of subjects: 0
Study 30556053 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia intervention (website + booklet)
Number of subjects: 552
Study 30556172 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticism as a management strategy
Number of subjects: 256
Study 30556332 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)/Nestorone (NES) combination gel applied by men (62 mg/8 mg)
Number of subjects: 24
Study 30556332 — intervention group
Group type: COMPARATOR
Intervention: Shirt covering the application site
Number of subjects: 24
Study 30556332 — intervention group
Group type: COMPARATOR
Intervention: Showering before contact
Number of subjects: 24
Study 30556457 — intervention group
Group type: EXPERIMENTAL
Intervention: Properly sized nasotracheal tubes (sizes 6.0-8.0)
Number of subjects: 40
Study 30542662 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised screening, prevention and care for tuberculosis and HIV
Number of subjects: 0
Study 30556630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 0
Study 30556630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 0
Study 30556630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 30557448 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission PTX3 levels
Number of subjects: 188
Study 30557448 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX3 combined with CURB-65
Number of subjects: 188
Study 30557521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity
Number of subjects: 475
Study 30557521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 475
Study 30557741 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless Motility Capsule (WMC)
Number of subjects: 167
Study 30557741 — intervention group
Group type: COMPARATOR
Intervention: Gastric Emptying Scintigraphy (GES)
Number of subjects: 167
Study 30558502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac positron emission tomography studies with 4-[
Number of subjects: 0
Study 30558502 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar scintigraphy or positron emission tomography
Number of subjects: 0
Study 30558581 — intervention group
Group type: EXPERIMENTAL
Intervention: RealRisks decision aid
Number of subjects: 40
Study 30558613 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating breakfast daily throughout childhood
Number of subjects: 995
Study 30558613 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily family dinner
Number of subjects: 995
Study 30558613 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating fast food less than once per week throughout childhood
Number of subjects: 995
Study 30558613 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating meals while watching television <1/week throughout childhood
Number of subjects: 995
Study 30558909 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (1 mg/kg three times per week subcutaneously, adjusted to 3 mg/kg three times per week if required) for up to 7 years
Number of subjects: 11
Study 30558909 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Number of subjects: 11
Study 30558987 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbralisib (800 mg once daily) plus Ibrutinib (420 mg for CLL, 560 mg for MCL)
Number of subjects: 44
Study 30558987 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbralisib plus Ibrutinib
Number of subjects: 44
Study 30559136 — intervention group
Group type: EXPERIMENTAL
Intervention: Afabicin (Debio 1450, AFN-1720)
Number of subjects: 0
Study 30559420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of an antisense oligonucleotide to restore correct splicing
Number of subjects: 10
Study 30559424 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5991
Number of subjects: 0
Study 30559424 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5991 in combination with bortezomib or venetoclax
Number of subjects: 0
Study 30559603 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-SELF© Plus Pain Control Program (PCP), 6-week intervention, weekly psychoeducational sessions
Number of subjects: 210
Study 30559603 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 210
Study 30559966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 187
Study 30559966 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise and Dietary Therapy (PED-t)
Number of subjects: 187
Study 30559966 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 187
Study 30559966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT and PED-t
Number of subjects: 187
Study 30561229 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 administered via prefilled syringe (PFS)
Number of subjects: 49
Study 30561229 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 administered via autoinjector (AI)
Number of subjects: 49
Study 30561229 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall impression of PFS and AI
Number of subjects: 49
Study 30561229 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference for AI
Number of subjects: 49
Study 30561229 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 49
Study 30561271 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine history
Number of subjects: 585
Study 30561271 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAD patients with migraine
Number of subjects: 585
Study 30561271 — intervention group
Group type: COMPARATOR
Intervention: SCAD patients without migraine
Number of subjects: 585
Study 30561367 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR in LAD
Number of subjects: 835
Study 30561367 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR in non-LAD
Number of subjects: 835
Study 30561563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 0
Study 30561563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hypergammaglobulinemia
Number of subjects: 0
Study 30562118 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-blood transcriptome profiling
Number of subjects: 0
Study 30562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception anemia (hemoglobin <12 g/dL)
Number of subjects: 1248
Study 30562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 1248
Study 30562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency among anemic cases
Number of subjects: 1248
Study 30562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 1248
Study 30562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection at enrolment
Number of subjects: 1248
Study 30562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation
Number of subjects: 1248
Study 30562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased mid-upper arm circumference
Number of subjects: 1248
Study 30562587 — intervention group
Group type: EXPERIMENTAL
Intervention: CMVPepVax (two injections at days 28 and 56 post-HCT)
Number of subjects: 0
Study 30563388 — intervention group
Group type: EXPERIMENTAL
Intervention: EmboTrap
Number of subjects: 40
Study 30563576 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrilobular emphysema
Number of subjects: 300
Study 30563576 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation markers
Number of subjects: 300
Study 30563754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) and autologous stem-cell transplantation (ASCT)
Number of subjects: 18
Study 30563818 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 (Prepared, Protected, emPowered) mobile app intervention
Number of subjects: 0
Study 30563818 — intervention group
Group type: EXPERIMENTAL
Intervention: P3+ mobile app intervention with adherence counseling via SMS
Number of subjects: 0
Study 30563818 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 30563875 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin added to chemotherapy
Number of subjects: 0
Study 30563875 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin as single-agent maintenance therapy
Number of subjects: 0
Study 30563875 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 30563931 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day)
Number of subjects: 84
Study 30564163 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning intervention in nursing homes
Number of subjects: 0
Study 30564163 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 30564373 — intervention group
Group type: EXPERIMENTAL
Intervention: QRISK2
Number of subjects: 673
Study 30564373 — intervention group
Group type: EXPERIMENTAL
Intervention: JBS3 'heart age'
Number of subjects: 673
Study 30564373 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP levels
Number of subjects: 673
Study 30564373 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy eligibility
Number of subjects: 673
Study 30564436 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus exercise-based cardiac rehabilitation (CR)
Number of subjects: 27
Study 30564436 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 27
Study 30564436 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Number of subjects: 27
Study 30564451 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 392
Study 30564451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 30564993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) method for golimumab
Number of subjects: 10
Study 30564993 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimen of golimumab
Number of subjects: 10
Study 30564993 — intervention group
Group type: EXPERIMENTAL
Intervention: User-friendliness evaluation via questionnaire
Number of subjects: 10
Study 30564993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal healing evaluation at week 14
Number of subjects: 10
Study 30565055 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention to reduce postprandial glucose (PPG)
Number of subjects: 37
Study 30565055 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 37
Study 30565371 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO stent treatment
Number of subjects: 1000
Study 30566600 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malaria patients
Number of subjects: 107
Study 30566600 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 107
Study 30566616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (170 participants)
Number of subjects: 376
Study 30566616 — intervention group
Group type: COMPARATOR
Intervention: Similar-aged controls (135 participants)
Number of subjects: 376
Study 30566616 — intervention group
Group type: COMPARATOR
Intervention: Late reproductive-aged controls (71 participants)
Number of subjects: 376
Study 30566661 — intervention group
Group type: EXPERIMENTAL
Intervention: STand Up Frequently From Stroke (STUFFS) program, an 8-week home-based sedentary behavior change intervention
Number of subjects: 25
Study 30567529 — intervention group
Group type: EXPERIMENTAL
Intervention: HDIL-2 + MAGE-A3 CI
Number of subjects: 18
Study 30567529 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance MAGE-A3 CI monotherapy
Number of subjects: 18
Study 30567529 — intervention group
Group type: COMPARATOR
Intervention: HDIL-2 alone
Number of subjects: 18
Study 30567548 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 78
Study 30567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse Reflectance Spectroscopy (DRS)
Number of subjects: 27
Study 30567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mode DRS measurements
Number of subjects: 27
Study 30568035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study 30568582 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based behavioral monitoring
Number of subjects: 0
Study 30568870 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct notification of cervical cytology results by the pathology department
Number of subjects: 0
Study 30568870 — intervention group
Group type: COMPARATOR
Intervention: Conveying results via the general practitioner (usual care)
Number of subjects: 0
Study 30569031 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat-rich diet (84% in severe AP)
Number of subjects: 407
Study 30569031 — intervention group
Group type: COMPARATOR
Intervention: Mild/moderate diet (72% in mild AP, 67% in moderate AP)
Number of subjects: 407
Study 30569031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits overall
Number of subjects: 407
Study 30569031 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent organ failure association
Number of subjects: 407
Study 30569038 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel nano-iron supplement
Number of subjects: 0
Study 30569038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30569586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scales-II (VABS-II)
Number of subjects: 0
Study 30569586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician Global Impression (CGI) scale
Number of subjects: 0
Study 30569586 — intervention group
Group type: EXPERIMENTAL
Intervention: VABS-II and CGI scale
Number of subjects: 0
Study 30569759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone intravitreal implant (ILUVIEN)
Number of subjects: 0
Study 30570077 — intervention group
Group type: EXPERIMENTAL
Intervention: Instituto Butantan seasonal trivalent influenza vaccine (TIV)
Number of subjects: 1253
Study 30570273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette demand and delay discounting (DD)
Number of subjects: 277
Study 30570273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette consumption assessment
Number of subjects: 277